“While the stock gained strongly on this development, it comes shortly after Alembic reported its financial results for the fourth quarter of FY25. The company posted a 17% year-on-year increase in revenue, reaching around ₹1,770 crore. However, its net profit declined by about 12% to ₹157 crore due to increased investment in R&D, manufacturing capacity, and regulatory compliance. Despite the dip in profit, the company’s EBITDA rose 9% to ₹286 crore, showing that its core operations remain strong.
The US business continues to be a major growth driver for Alembic. In the fourth quarter, US sales contributed around ₹521 crore, with strong year-on-year growth. The company has also been actively launching new products and investing in new facilities –in Jarod and Karakhadi — to support future growth.
Investor reaction to the USFDA approval has been positive, as the market sees this as a sign of Alembic’s growing capabilities in complex generics. Although recent profit numbers were slightly lower, the long-term outlook remains promising with more product launches and international market expansion expected.
The sharp rise in Alembic Pharma’s share price reflects investor confidence in its US growth strategy and the commercial potential of its newly approved cancer drug.